Literature DB >> 7023829

Pharmacokinetic and pharmacodynamic modeling in vivo.

N H Holford, L B Sheiner.   

Abstract

A rational goal of clinical pharmacology is to described and predict the relationship between drug dose and drug effect. The processes involved in the dose-effect relationship can be described in two main categories - pharmacokinetics, which is concerned with factors affecting the dose-active site concentration process, and pharmacodynamics, which describes the active site concentration-effect process. The development of models of the dose-effect relationship will be described starting with dose-effect models which do not distinguish between pharmacokinetics and pharmacodynamics, progressing to models based upon pharmacokinetic predictions of the active site concentration, and finally describing models which combine both pharmacokinetic and pharmacodynamic models to predict both active site concentrations and the drug effect.

Mesh:

Substances:

Year:  1981        PMID: 7023829

Source DB:  PubMed          Journal:  Crit Rev Bioeng        ISSN: 0731-6984


  50 in total

1.  Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay.

Authors:  L M Levasseur; H Faessel; H K Slocum; W R Greco
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

Review 2.  Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.

Authors:  J V Gobburu; P J Marroum
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

4.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

5.  Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.

Authors:  Euitae Kim; Oliver D Howes; Bo-Hyung Kim; Jae Min Jeong; Jae Sung Lee; In-Jin Jang; Sang-Goo Shin; Federico E Turkheimer; Shitij Kapur; Jun Soo Kwon
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-21       Impact factor: 6.200

6.  Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models", Clin Pharmacokin 6:429-453 (1981)-The Backstory.

Authors:  Nick Holford
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

7.  Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers.

Authors:  H Derendorf; H Möllmann; M Krieg; S Tunn; C Möllmann; J Barth; H J Röthig
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

Review 8.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

9.  Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam.

Authors:  E H Ellinwood; D G Heatherly; A M Nikaido; T D Bjornsson; C Kilts
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration.

Authors:  P K Yeung; J D Feng; S J Buckley
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.